Although seemingly more convenient, idraparinux is potentially unsafe in cancer patients due to its long half-life of approximately 4 days and the lack of an available antidote for reversal of the ...

AstraZeneca's anticoagulant reversal agent Andexxa was given an accelerated approval by the FDA in 2018, but the company's plan to get that upgraded to a full approval is facing some pushback.

A variety of antidotes have been reported to treat SSRI-induced sexual dysfunction effectively; however, virtually all the data on these agents are derived from open case reports and case series.